Multiple Myeloma

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

FDA Alert
FDA website on computer screen
FDA Alert
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase-fihj for Adults with Relapsed or Refractory Multiple Myeloma
03/06/2026
Kate Young
Based on findings from the phase 3 MajesTEC-3 trial, the FDA announced the approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who...
03/06/2026
FDA Alert
fda phone
FDA Alert
FDA Approves Daratumumab and Hyaluronidase-Fihj Plus VRd For Transplant-Ineligible Newly Diagnosed Multiple Myeloma
02/05/2026
Anthony Calabro, MA
The FDA approval expands frontline treatment options for adults with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant, based on randomized trial data showing...
02/05/2026
research summary
shutterstock image
research summary
Optimized Step-Up Dosing Reduces Cytokine Release Syndrome with Elranatamab in Relapsed or Refractory Multiple Myeloma
12/22/2025
Anthony Calabro, MA
A pooled analysis of 4 MagnetisMM trials evaluated dosing strategies for elranatamab, a BCMA-CD3 bispecific antibody, to identify the optimal regimen that mitigates cytokine release syndrome in patients...
12/22/2025

Interactive Features

Pop Quiz
physician at desk
Pop Quiz
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
12/17/2025
Ashton L. Stahl
As researchers continue exploring early-intervention strategies for high-risk smoldering multiple myeloma, understanding the basic pathophysiology of plasma cell disorders (and the targets of emerging...
12/17/2025

Clinical Insights

Multidisciplinary Dialogue, Ep. 8
harrison
Multidisciplinary Dialogue, Ep. 8
Renal Tubular Acidosis, Metabolic Alkalosis
09/02/2024
In this episode, Anil Harrison, MD, speaks with Dharminder Singh, MD, about the evaluation of renal tubular acidosis (RTA) and how to evaluate metabolic alkalosis. The first patient case presentation is a...
09/02/2024
expert Q&A
richter headshot
expert Q&A
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual...
10/18/2022